Skip Navigation


Human Molecular Genetics Advance Access originally published online on February 5, 2004
This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/suppl_1/R169    most recent
ddh078v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mein, C. A.
Right arrow Articles by Munroe, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mein, C. A.
Right arrow Articles by Munroe, P. B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Molecular Genetics, 2004, Vol. 13, Review Issue 1 R169-R175
DOI: 10.1093/hmg/ddh078

Genetics of essential hypertension

Charles A. Mein, Mark J. Caulfield, Richard J. Dobson and Patricia B. Munroe*

Clinical Pharmacology and The Genome Centre, The William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK

Received January 16, 2004; Accepted January 27, 2004


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
Essential hypertension affects 1 billion people worldwide and its genetic basis is well established. For this review we surveyed the literature on the genetics of hypertension during the past 18 months and we now report the highlights. There has been publication of the two largest genome scans for blood pressure and new loci including significant linkage to chromosome 6q have been reported. The molecular basis of Gordon's syndrome has been partially unravelled with a dual function for WNK4 in ion transport regulation being discovered. There has also been progress in narrowing rodent quantitative trait loci using congenic approaches and several linkage peaks have now been demonstrated to have more than one loci. We also report some of the initial findings from pharmacogenetic studies.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
Human hypertension affects 1 billion people worldwide and is implicated in 7.1 million deaths each year from ischaemic heart disease and stroke (www.who.int/en/index.html). Recent alarming data suggests that by applying modern diagnostic thresholds of 140/90 mmHg, a 55-year-old with normal blood pressure (BP) has a 90% lifetime prospect of developing hypertension (1). It is clear from family and epidemiological studies that hypertension arises from a complex interplay between genetic and environmental lifestyle exposures including dietary sodium intake, excess alcohol consumption and body weight (2). In addition, twin studies and segregation analyses have shown that between one-third and one-half of the inter-individual variation of BP is heritable (2,3).

The last decade has seen substantial progress towards detection of genes underpinning several Mendelian hypertensive traits, which may present early in life with distinct phenotypes (4,5). At the same time mapping strategies and genomic screening with experimental models of hypertension have offered insights into the possible genetic architecture of the trait in humans (6). This has generated opportunities for comparative mapping of syntenic regions and loci from rodent to man (69). At present most published data on human essential hypertension (EH) arises from candidate gene studies and preliminary reports from several genome screens on a variety of hypertensive phenotypes (10,11). In this review we focus upon progress toward understanding the genetic basis of hypertension during the last 18 months.


    GENOME SCREENS FOR BLOOD PRESSURE TRAITS IN MAN
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
There are now many publications describing the results of genome-wide screens for genes controlling BP. The majority have reported numerous chromosomal regions with suggestive evidence of linkage (reviewed in 10,12).

In the past 12 months the results of two of the largest genome scans completed to date have been reported: the US National Institute of Health funded Family Blood Pressure Program (FBPP) (1316) and the Medical Research Council funded British Genetics of Hypertension (BRIGHT) study (11). The FBPP comprises four multi-centre networks (GENOA, GenNet, HyperGEN and SAPPHIRe); each centre has recruited participants with different selection criteria from multiple ethnic groups. None of the four networks found any chromosomal region with genome-wide significant evidence of linkage. The highest LOD score, 2.96 was linked to diastolic BP on chromosome 1q in Caucasians using variance components analysis (15). The authors reported that there were no compelling candidate genes in this chromosomal region.

In contrast the BRIGHT study reported a principle locus for hypertension on chromosome 6q (LOD score of 3.21) that attained genome-wide significance using a locus counting method and three further loci with suggestive evidence of linkage on chromosomes 2q, 5q and 9q (11). The BRIGHT study represents the largest homogenous Caucasian resource that has been published to date (1599 families, comprising 2010 sibling-pairs). Comparison of results with the FBPP do not reveal any overlap between the regions found. In one way this is surprising, as we would expect some overlap within the same ethnic group. It is feasible, however, that differences in the results are attributable to subtle differences in the phenotypes that have been studied or differences in statistical power. It is important to note that only half of the FBPP recruits have been studied at this point.

In addition to the FBPP and the BRIGHT study, three other smaller genome screens were published recently. Von Wowern et al. (17) performed a genome-scan of 91 Scandinavian families with early onset hypertension. They found that one region on chromosome 14 attained genome-wide significance and a locus on chromosome 2 with suggestive linkage. A genome-scan for pulse pressure was also reported (18). In this study 26 large Utah pedigrees were studied and two regions were found to contain loci with genome-wide suggestive evidence of linkage, chromosomes 8p and 12q. This is the second genome screen reported for pulse pressure, but the results are not concordant with a smaller study in Mexican Americans (19). Once again this demonstrates the difficulties being encountered in replicating genome scan results, even with apparently the same phenotype, albeit from a different ethnic group.

Gong et al. (20) studied a large Chinese hypertensive kindred (n=387 individuals) and a locus on chromosome 12p was discovered. This region overlaps with the region containing the gene for autosomal dominant hypertension with type E brachydactyly, a condition observed a few years ago in a Turkish kindred (21). Indeed, a recent paper has just described the genetic basis of this condition in the Turkish family; affected individuals have a complex chromosomal rearrangement involving a deletion, a reinsertion and an inversion (22). Three candidate genes were assessed (ATP-dependent potassium channel KIR6.1, a sulfonyl urea receptor SUR2 and the phosphodiesterase PDE3A) and some functional studies were performed, but no mutations or functional effects were found in the six patients studied. The authors report that the candidate region is gene-poor, however there are some expressed sequence tags that need to be fully characterized. The cloning of this gene will be of major interest as it is possible that it will also be involved in EH.

Each genome scan reported differs in numbers, ethnicity, family types, design and the phenotyping strategy (there are studies with both hypertension as a discrete trait and those that have taken BP as a continuous variable). We have summarized the main findings of all human genome scans undertaken thus far, including pre-eclampsia to ascertain if there are any chromosomal regions that have been found in more than one study (Fig. 1). We observed all human chromosomes except 13 and 20 to have BP, hypertension or pre-eclampsia loci. Indeed chromosomes 1, 2, 8, 11, 12, 15, 16, 18 and 19 have regions that have been found in more than one study, yielding some encouraging consistent support for BP loci. Chromosome 2 has three cytogenetic intervals, 2p25.3–p16.3, 2p16.1–p12 and 2q23.3–q24.3, where more than one study has mapped a blood pressure locus. The regions found by Laivuori et al. (23) and Angius et al. (24) directly overlap, similarly further along the chromosome the regions delineated by Caulfield et al. (11) and Zhu et al. (25) completely overlap. There are also three chromosomal regions with partially overlapping data. In these intervals both BP and pre-eclampsia loci have been mapped. The use of different markers, study designs and poor precision with linkage data make it difficult to know if the studies have found the same gene. The challenge is to identify which of these loci are genuine and it will be the results of fine mapping or grid tightening in the first instance that will yield this information. The results in the main have been disappointing as very few studies reported genome-wide significant loci. However, some of the loci are likely to survive grid tightening, albeit not necessarily with augmented LOD scores; this will serve to inform direct and indirect linkage disequilibrium analyses.



View larger version (57K):
[in this window]
[in a new window]
 
Figure 1. Genome scan results for blood pressure, hypertension and pre-eclampsia genes. Ideograms (adapted with permission from Ensembl (http//:nar.oupjournals.org/cgi/content/full/30/1/38) are shown for each human chromosome annotated with genetic markers linked to blood pressure, hypertension and pre-eclampsia. Mapping information was obtained from the literature, see Table 1 in the review by Garcia et al. (12) and the recent data described in this review (9,1113,1519,2325,7793). The results of all genome-scans to date are summarised. Genetic markers linked to the trait and 10 Mb either side are indicated with a black vertical line for all studies except for the genome-scans reported by Camp et al. (18) and Harrap et al. (78). For these studies we have indicated the markers flanking the linked region. The markers highlighted in red indicate that the marker is significantly linked to the trait whilst markers highlighted in blue are those demonstrating suggestive evidence of linkage. Only markers demonstrating the highest LOD scores in each study are illustrated, and the reference of the study is indicated in parentheses.

 

    THE WNK KINASES—NEW INSIGHTS INTO BLOOD PRESSURE REGULATING MECHANISMS
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
Mutations in the genes encoding the WNK kinases 1 and 4 cause pseudohypoaldosteronism type II or Gordon's syndrome, a rare autosomal dominant condition that has hypertension as a cardinal phenotypic feature (5). It has been shown that deletions within intron 1 of the WNK1 gene and missense mutations in WNK4 are responsible for the condition (5). The WNK kinases are both expressed in the kidney within the distal convoluted tubule and the collecting ducts and have been implicated in net renal re-absorption, as well as net potassium and hydrogen excretion (5). Over the past year there has been a series of papers that have shed light on the mechanisms by which mutations in the WNK kinases lead to the distinct phenotype observed in Gordon's syndrome patients (hypertension, hyperkalaemia and metabolic acidosis) and the regulation of ion transport in the distal nephron of the kidney.

The clinical features of Gordon's syndrome can be corrected with thiazide diuretics; these drugs are specific inhibitors of the sodium chloride co-transporter (NCCT). This observation fuelled speculation that the defect in Gordon's is due to increased activity of NCCT. Recent exciting data from Wilson et al. (26) and Yang et al. (27) have now shown that WNK 4 directly interacts with the NCCT in vitro and inhibits its activity by reducing the numbers of the receptors on the cell surface. Importantly constructs with the Gordon's specific missense mutations lose their ability to suppress NCCT which would lead to net sodium retention. This direct interaction provides an explanation for the hypertension, the biochemical phenotype and the sodium retention observed in Gordon's syndrome.

Hyperkalaemia is also observed in Gordon's syndrome and in a set of elegant experiments by Kahle and colleagues it has recently been demonstrated that WNK4 also directly interacts with the potassium channel ROMK demonstrating a dual role for WNK4 in ion transport regulation (28). Using Xenopus laevis oocytes it was found that the potassium current exuded by expression of ROMK2 was inhibited by WNK4, this interaction was not kinase-dependent, and that the mechanism is via inhibition of endocytosis of ROMK. Constructs with mutations causing Gordon's syndrome (Q562E and E559K) were found to increase inhibition of ROMK. The clinical picture of Gordon's patients with mutations in WNK4 now has an explanation at the molecular level. Although further work is required to determine other regulators of WNK4 and its molecular interactions, this illustrates how the combination of genetics and functional genomics can offer access to unexpected biochemical interactions.

The exact mechanism by which mutations in WNK1 cause Gordon's syndrome has yet to be fully elucidated. This protein is expressed in several epithelia and in vitro it has been observed that it prevents WNK4 interacting with the NCCT (27,29). In the past year the genomic structure of WNK1, its promoters and enhancers have been published and it has been demonstrated that there are several isoforms (30). WNK1 knockout mice have also been generated via a functional screening programme for genes regulating BP. Heterozygous mice were found to be viable with low BP and with no other notable phenotype; homozygous mice died during embryonic development at or around day 13 (31). Using a Taqman assay it was demonstrated that WNK1 mRNA expression was reduced by 49 and 50.1% in the kidney and the thymus, respectively, in the heterozygote. The creation of this WNK1 knockout model will undoubtedly prove to be extremely useful for helping to elucidate mechanisms by which mutations in WNK1 lead to hypertension.


    LINKAGE SCREENS IN RODENT MODELS OF HYPERTENSION
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
During the 1990s crosses between hypertensive strains including the Dahl salt-sensitive rat and the spontaneously hypertensive rat, and inbred non-hypertensive strains like the Wistar Kyoto rat, Lewis and Milan normotensive strain, showed linkage to BP related traits with all but three rat chromosomes, RNO 6,11 and 15 (reviewed in 6). Recent efforts have focused on validating linkage results from some of these crosses (32) or using methods with different experimental designs to identify novel BP loci from varied rat strains (33,34).

Traditional experiments to identify rodent BP loci using linkage have crossed inbred strains with extreme (hypertensive versus non-hypertensive) phenotypes. Important loci from other strains will be missed by this approach and it has no power to identify if different hypertensive strains share loci in common (33). To address the first point Kloting et al. (33) used a novel approach of back-crossing wild rat to wild rat–spontaneously hypertensive rat hybrids to identify new BP loci. These authors identified suggestive linkage to RNO 2, 5, 7 and 11 (the first on RNO11) to hypertension as well other metabolic syndrome traits (33). To test the contribution of blood pressure quantitative trait loci (QTL) between hypertensive strains Garrett et al. (34) crossed two hypertensive strains, the Dahl salt sensitive and the albino surgery rat. This confirmed two loci previously identified in the Dahl salt sensitive on RNO2 and RNO4 and identified a third locus on RNO8 specific to the albino surgery rat. The large number of loci identified within inbred rat strains reflects the picture we are now seeing in human studies.


    CONGENIC STUDIES IDENTIFY SEVERAL QTL PER LINKAGE
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
Linkage studies have identified many QTL, each tens of centimorgans in length, on most rat chromosomes (6). The challenge to identify susceptible variants within these large QTL has seen attention shift to congenic mapping (35). Recently published work has focused on dissecting linked regions on RNO1 (3643), RNO2 (4447), RNO3 (48), RNO5 (49,50), RNO7 (51), RNO8 (52), RNO9 (53) and RNO16 (54). We will focus on the recent work on RNO10 as an illustration (41,43,5557).

In a series of congenic lines with DNA from either the Milan normotensive strain or the Lewis rat introgressed onto the genetic background of the Dahl salt-sensitive rat, Garrett et al. (43) have identified blood pressure QTL of 2.6 and 3.2 cM separated by 24 cM on RNO10. The more terminal of these regions is only seen in congenics derived from one of the normotensive strains (Milan), implying that the other (Lewis) has a BP raising allele at this position (43). These data are supported by congenics reported by Sivo et al. (56) and later by Palijan et al. (43,57). Interestingly these congenic lines are not consistent with a role for the potential candidate genes: inducible nitric oxide synthase (Nos2), angiotensin 1-converting enzyme 1 (Ace) gene and protein kinase lysine deficient (Prkwnk4) in the hypertensive phenotype of the Dahl salt sensitive rat. As corroborative evidence, Monti et al. (58) found no difference in sequence or expression levels of Prkwnk4 between the stroke prone hypertensive or the Wistar Kyoto rat.

It is important to note that using congenic analysis several BP QTL are also seen for single linkage peaks on RNO1 (36,37,42,59,60), RNO2 (4447), RNO3 (61) and RNO5 (49). This parallels observations made in other complex diseases such as type 1 diabetes (62,63). There are two implications for human genetics: firstly the number of hypertension loci may be more than many researchers had anticipated and secondly, in order to detect these genes, analytical techniques that can tease out closely linked, or interacting loci must be developed.


    IMPLICATING INDIVIDUAL GENES AT RODENT QTL
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
While congenic mapping is a powerful approach it is unlikely to narrow QTLs to a region much smaller than 200 kb in size. For example, the 177 kb segment of chromosome 7 that was identified by Garrett and Rapp (51), although relatively small, contained eight positional candidate genes, one of which was aldosterone synthase Cyp11b1, the gene involved in glucocorticoid-remediable aldosteronism and human hypertension (51,64). In order to implicate one of these genes, other technologies such as transcription profiling, knockout, knockin, transgenic models and small interfering RNA (siRNA) must be used.

A combination of congenic mapping and transcription profiling was successfully used to implicate CD36 in insulin resistance (65). Recently a similar approach has been applied by McBride et al. (66), who compared the transcriptional profile in kidneys from the SHR-stroke prone rat and a congenic strain with a 22 cM region of WKY chromosome 2. They identified a single transcript, glutathione S-transferase µ-type 2 (Gstm2) up-regulated in the normotensive lines (66). It remains to be shown if this effect contributes to the hypertensive phenotype or is a secondary phenotype (66).

Knockout, knockin and transgenic models have yet to be used to help resolve the contribution of individual genes within a congenic region to hypertension, although there has been much interest in their use in understanding genes from known pathways particularly the renin–angiotensin system. Likewise siRNA (67) has yet to be used systematically to target gene expression from a congenic region. However, the first reported use of this technology in hypertension suggests it may be a powerful new tool for unravelling hypertension genetics. Snyder et al. (68,69) used siRNA to block expression of Nedd4 and Nedd4-2, both regulators of the renal epithelial sodium channel (ENaC), the gene mutated in Liddle's syndrome. It was shown that Nedd4-2 regulates ENaC levels in a steroid hormone-dependent fashion (69). Moreover, this effect was ameliorated in cell lines expressing a variant allele of ENaC from an individual with Liddle's syndrome (69). Development of these approaches and others in a targeted systematic way will be required to understand the role of individual genes within congenic intervals.


    PHARMACOGENETICS IN HYPERTENSION
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
The latest studies of non-pharmacological approaches and meta-analysis of drug-based intervention trials indicate that there are several effective strategies that can be deployed to reduce BP (70,71). In spite of guidelines encouraging the pursuit of good blood pressure control by use of several concurrent medications, there is strong evidence that BP control is sub-optimal in two-thirds of hypertensives (www.nhlbi.nih.gov/guidelines/hypertension/, www.hyp.ac.uk/bhs/) (72). One of the problems we face is our limited ability to tailor selection of medication to maximize efficacy and minimize adverse reactions in an individual.

The available evidence on the potential of pharmacogenetics to enable prediction of therapeutic effect on BP has recently been evaluated (73). Many of the initial studies have included small numbers, relied on single dosing rather than chronic dosing, used single nucleotide polymorphisms (SNPs), instead of haplotype tag SNPs and have not controlled for exposures, such as dietary sodium, which could attenuate or enhance responsiveness (73).

Pharmacogenetic studies in hypertension have begun to report larger sample sizes. Recently BP response to a thiazide diuretics was evaluated in 291 unrelated Hispanic men and women using SNPs which may be of functional importance within four common cardiovascular candidate genes (74). After adjustment for covariates only the endothelial nitric oxide synthase GLU298ASP variant was associated with a small BP response to hydrochlorthiazide (74). In a separate study the prediction of BP response to irbesartan or atenolol in reduction of left ventricular hypertrophy was tested by simultaneously genotyping 74 SNPs drawn from multiple candidate genes, which might influence target response, using a minisequencing microarray approach in the 97 hypertensive participants (75). The authors acknowledge the difficulty of appropriate adjustment of statistical analysis to account for multiple hypothesis testing and have accordingly accepted a greater stringency for statistical significance (75). The results indicate that plausible candidate gene SNPs from the alpha 2 adrenoceptor and ß2 adrenoceptor SNPs predicted response to atenolol, whereas angiotensinogen, angiotensin-converting enzyme and aldosterone synthase SNPs were related to irbesartan response (75). This type of high-throughput approach incorporating comprehensive analysis of haplotype tagging SNPs in multiple candidates that might affect target response or metabolism of antihypertensives is beginning to be employed in extensive repositories of hypertensives associated with large-scale endpoint trials.


    CONCLUDING REMARKS
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 
At this time it is of note that all of the genes responsible for a hypertensive phenotype have come from studies of monogenic diseases, and all are kidney-specific, operating by affecting sodium balance. There are no positionally cloned genes identified to date in either rodent models or the human hypertension phenotype. There can be no doubt that linkage data published thus far in both human and animal models of hypertension attest to the complex polygenic nature of the disorder. In addition, there is still no evidence that BP loci identified in rodents and humans will be the same, but it seems plausible that each linkage peak in the rodent may comprise several QTL and this may also hold true for the human condition. This coupled with the lower power of linkage screens means that the number of human hypertension loci is most probably in the order of tens of genes. Recently reported sib-pair genome screens suggest that there are no genes with a major effect. Accordingly, it is likely that we are looking for many genes with a genotype relative risk of 1.2–1.5. The current challenge is to confirm linkage peaks and identify disease predisposing variants using new resources that are becoming available, for example the Hapmap project (76) and new genotyping technologies. We also need to gear up for genome-wide association studies with appropriate power to detect genes with a lower relative risk, this will ultimately enable comprehensive pharmacogenetic studies.


    ACKNOWLEDGEMENTS
 
We are extremely grateful to the Medical Research Council, The British Heart Foundation, Joint Research Board and The Special Trustees of St Bartholomew's Hospital for funding the research.


    FOOTNOTES
 
* To whom correspondence should be addressed. Tel: +44 2078823410; Fax: +44 2078823408; Email: p.b.munroe{at}qmul.ac.uk


    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 GENOME SCREENS FOR BLOOD...
 THE WNK KINASES—NEW...
 LINKAGE SCREENS IN RODENT...
 CONGENIC STUDIES IDENTIFY...
 IMPLICATING INDIVIDUAL GENES AT...
 PHARMACOGENETICS IN HYPERTENSION
 CONCLUDING REMARKS
 REFERENCES
 

  1. Vasan, R.S., Beiser, A., Seshadri, S., Larson, M.G., Kannel, W.B., D'Agostino, R.B. and Levy, D. (2002) Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA, 287, 1003–1010.[Abstract/Free Full Text]

  2. Snieder, H., Harshfield, G.A. and Treiber, F.A. (2003) Heritability of blood pressure and hemodynamics in African- and European-American youth. Hypertension, 41, 1196–1201.[Abstract/Free Full Text]

  3. Ward, R. (1990) Familial aggregation and genetic epidemiology of blood pressure. In Laragh, J.H. and Brenner, B.M. (eds), Hypertension: Pathophysiology, Diagnosis and Management. Raven Press, New York, pp. 81–100.

  4. Lifton, R.P., Gharavi, A.G. and Geller, D.S. (2001) Molecular mechanisms of human hypertension. Cell, 104, 545–556.[CrossRef][Web of Science][Medline]

  5. Wilson, F.H., Disse-Nicodeme, S., Choate, K.A., Ishikawa, K., Nelson-Williams, C., Desitter, I., Gunel, M., Milford, D.V., Lipkin, G.W., Achard, J.M. et al. (2001) Human hypertension caused by mutations in WNK kinases. Science, 293, 1107–1112.[Abstract/Free Full Text]

  6. Rapp, J.P. (2000) Genetic analysis of inherited hypertension in the rat. Physiol. Rev., 80, 135–172.[Abstract/Free Full Text]

  7. Kreutz, R., Hubner, N., James, M.R., Bihoreau, M.T., Gauguier, D., Lathrop, G.M., Ganten, D. and Lindpaintner, K. (1995) Dissection of a quantitative trait locus for genetic hypertension on rat chromosome 10. Proc. Natl Acad. Sci. USA, 92, 8778–8782.[Abstract/Free Full Text]

  8. Julier, C., Delepine, M., Keavney, B., Terwilliger, J., Davis, S., Weeks, D.E., Bui, T., Jeunemaitre, X., Velho, G., Froguel, P. et al. (1997) Genetic susceptibility for human familial essential hypertension in a region of homology with blood pressure linkage on rat chromosome 10. Hum. Mol. Genet., 6, 2077–2085.[Abstract/Free Full Text]

  9. Levy, D., DeStefano, A.L., Larson, M.G., O'Donnell, C.J., Lifton, R.P., Gavras, H., Cupples, L.A. and Myers, R.H. (2000) Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the Framingham heart study. Hypertension, 36, 477–483.[Abstract/Free Full Text]

  10. Samani, N.J. (2003) Genome scans for hypertension and blood pressure regulation. Am. J. Hypertens., 16, 167–171.[CrossRef][Web of Science][Medline]

  11. Caulfield, M., Munroe, P., Pembroke, J., Samani, N., Dominiczak, A., Brown, M., Benjamin, N., Webster, J., Ratcliffe, P., O'Shea, S. et al. (2003) Genome-wide mapping of human loci for essential hypertension. Lancet, 361, 2118–2123.[CrossRef][Web of Science][Medline]

  12. Garcia, E.A., Newhouse, S., Caulfield, M.J. and Munroe, P.B. (2003) Genes and hypertension. Curr. Pharm. Des., 9, 1679–1689.[CrossRef][Web of Science][Medline]

  13. Rao, D.C., Province, M.A., Leppert, M.F., Oberman, A., Heiss, G., Ellison, R.C., Arnett, D.K., Eckfeldt, J.H., Schwander, K., Mockrin, S.C. et al. (2003) A genome-wide affected sibpair linkage analysis of hypertension: the HyperGEN network(1). Am. J. Hypertens., 16, 148–150.[CrossRef][Web of Science][Medline]

  14. Kardia, S.L.R., Rozek, L.S., Krushkal, J., Ferrell, R.E., Turner, S.T., Hutchinson, R., Brown, A., Sing, C.F. and Boerwinkle, E. (2003) Genome-wide linkage analyses for hypertension genes in two ethnically and geographically diverse populations. Am. J. Hypertens., 16, 154–157.[CrossRef][Web of Science][Medline]

  15. Thiel, B.A., Chakravarti, A., Cooper, R.S., Luke, A., Lewis, S., Lynn, A., Tiwari, H., Schork, N.J. and Weder, A.B. (2003) A genome-wide linkage analysis investigating the determinants of blood pressure in whites and African Americans. Am. J. Hypertens., 16, 151–153.[CrossRef][Web of Science][Medline]

  16. Ranade, K., Hinds, D., Hsiung, C.A., Chuang, L.-M., Chang, M.-S., Chen, Y.-T., Pesich, R., Hebert, J., Chen, Y.-D.I. and Dzau, V. (2003) a genome scan for hypertension susceptibility loci in populations of Chinese and Japanese origins. Am. J. Hypertens., 16, 158–162.[CrossRef][Web of Science][Medline]

  17. von Wowern, F., Bengtsson, K., Lindgren, C.M., Orho-Melander, M., Fyhrquist, F., Lindblad, U., Rastam, L., Forsblom, C., Kanninen, T., Almgren, P. et al. (2003) A genome wide scan for early onset primary hypertension in Scandinavians. Hum. Mol. Genet., 12, 2077–2081.[Abstract/Free Full Text]

  18. Camp, N.J., Hopkins, P.N., Hasstedt, S.J., Coon, H., Malhotra, A., Cawthon, R.M. and Hunt, S.C. (2003) Genome-wide multipoint parametric linkage analysis of pulse pressure in large, extended utah pedigrees. Hypertension, 42, 322–328.[Abstract/Free Full Text]

  19. Atwood, L.D., Samollow, P.B., Hixson, J.E., Stern, M.P. and MacCluer, J.W. (2001) Genome-wide linkage analysis of pulse pressure in Mexican Americans. Hypertension, 37, 425–428.[Abstract/Free Full Text]

  20. Gong, M., Zhang, H., Schulz, H., Lee, Y.A., Sun, K., Bahring, S., Luft, F.C., Nurnberg, P., Reis, A., Rohde, K. et al. (2003) Genome-wide linkage reveals a locus for human essential (primary) hypertension on chromosome 12p. Hum. Mol. Genet., 12, 1273–1277.[Abstract/Free Full Text]

  21. Schuster, H., Wienker, T.E., Bahring, S., Bilginturan, N., Toka, H.R., Neitzel, H., Jeschke, E., Toka, O., Gilbert, D., Lowe, A. et al. (1996) Severe autosomal dominant hypertension and brachydactyly in a unique Turkish kindred maps to human chromosome 12. Nat. Genet., 13, 98–100.[CrossRef][Web of Science][Medline]

  22. Bahring, S., Rauch, A., Toka, O., Schroeder, C., Hesse, C., Siedler, H., Fesus, G., Haefeli, W.E., Busjahn, A., Aydin, A. et al. (2004) Autosomal-dominant hypertension with type E brachydactyly is caused by rearrangement on the short arm of chromosome 12. Hypertension, 43, 471–476.[Abstract/Free Full Text]

  23. Laivuori, H., Lahermo, P., Ollikainen, V., Widen, E., Haiva-Mallinen, L., Sundstrom, H., Laitinen, T., Kaaja, R., Ylikorkala, O. and Kere, J. (2003) Susceptibility loci for preeclampsia on chromosomes 2p25 and 9p13 in Finnish families. Am. J. Hum. Genet., 72, 168–177.[CrossRef][Web of Science][Medline]

  24. Angius, A., Petretto, E., Maestrale, G.B., Forabosco, P., Casu, G., Piras, D., Fanciulli, M., Falchi, M., Melis, P.M., Palermo, M. et al. (2002) A new essential hypertension susceptibility locus on chromosome 2p24-p25, detected by genomewide search. Am. J. Hum. Genet., 71, 893–905.[CrossRef][Web of Science][Medline]

  25. Zhu, D.L., Wang, H.Y., Xiong, M.M., He, X., Chu, S.L., Jin, L., Wang, G.L., Yuan, W.T., Zhao, G.S., Boerwinkle, E. et al. (2001) Linkage of hypertension to chromosome 2q14-q23 in Chinese families. J. Hypertens., 19, 55–61.[CrossRef][Web of Science][Medline]

  26. Wilson, F.H., Kahle, K.T., Sabath, E., Lalioti, M.D., Rapson, A.K., Hoover, R.S., Hebert, S.C., Gamba, G. and Lifton, R.P. (2003) Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc. Natl Acad. Sci. USA, 100, 680–684.[Abstract/Free Full Text]

  27. Yang, C.L., Angell, J., Mitchell, R. and Ellison, D.H. (2003) WNK kinases regulate thiazide-sensitive Na-Cl cotransport. J. Clin. Invest., 111, 1039–1045.[CrossRef][Web of Science][Medline]

  28. Kahle, K.T., Wilson, F.H., Leng, Q., Lalioti, M.D., O'Connell, A.D., Dong, K., Rapson, A.K., MacGregor, G.G., Giebisch, G., Hebert, S.C. et al. (2003) WNK4 regulates the balance between renal NaCl reabsorption and K+ secretion. Nat. Genet., 35, 372–376.[CrossRef][Web of Science][Medline]

  29. Choate, K.A., Kahle, K.T., Wilson, F.H., Nelson-Williams, C. and Lifton, R.P. (2003) WNK1, a kinase mutated in inherited hypertension with hyperkalemia, localizes to diverse Cl--transporting epithelia. Proc. Natl Acad. Sci. USA, 100, 663–668.[Abstract/Free Full Text]

  30. Delaloy, C., Lu, J., Houot, A.M., Disse-Nicodeme, S., Gasc, J.M., Corvol, P. and Jeunemaitre, X. (2003) Multiple promoters in the WNK1 gene: one controls expression of a kidney-specific kinase-defective isoform. Mol. Cell. Biol., 23, 9208–9221.[Abstract/Free Full Text]

  31. Zambrowicz, B.P., Abuin, A., Ramirez-Solis, R., Richter, L.J., Piggott, J., BeltrandelRio, H., Buxton, E.C., Edwards, J., Finch, R.A., Friddle, C.J. et al. (2003) Wnk1 kinase deficiency lowers blood pressure in mice: a gene-trap screen to identify potential targets for therapeutic intervention. Proc. Natl Acad. Sci. USA, 100, 14109–14114.[Abstract/Free Full Text]

  32. Kato, N., Mashimo, T., Nabika, T., Cui, Z.H., Ikeda, K. and Yamori, Y. (2003) Genome-wide searches for blood pressure quantitative trait loci in the stroke-prone spontaneously hypertensive rat of a Japanese colony. J. Hypertens., 21, 295–303.[CrossRef][Web of Science][Medline]

  33. Kloting, I., Kovacs, P. and van den Brandt, J. (2001) Quantitative trait loci for body weight, blood pressure, blood glucose, and serum lipids: linkage analysis with wild rats (Rattus norvegicus). Biochem. Biophys. Res. Commun., 284, 1126–1133.[CrossRef][Web of Science][Medline]

  34. Garrett, M.R., Joe, B., Dene, H. and Rapp, J.P. (2002) Identification of blood pressure quantitative trait loci that differentiate two hypertensive strains. J. Hypertens., 20, 2399–2406.[CrossRef][Web of Science][Medline]

  35. Wakeland, E., Morel, L., Achey, K., Yui, M. and Longmate, J. (1997) Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol. Today, 18, 472–477.[CrossRef][Web of Science][Medline]

  36. Joe, B., Garrett, M.R., Dene, H. and Rapp, J.P. (2003) Substitution mapping of a blood pressure quantitative trait locus to a 2.73 Mb region on rat chromosome 1. J. Hypertens., 21, 2077–2084.[CrossRef][Web of Science][Medline]

  37. Frantz, S., Clemitson, J.R., Bihoreau, M.T., Gauguier, D. and Samani, N.J. (2001) Genetic dissection of region around the Sa gene on rat chromosome 1: evidence for multiple loci affecting blood pressure. Hypertension, 38, 216–221.[Abstract/Free Full Text]

  38. Lo, M., Liu, K.L., Clemitson, J.R., Sassard, J. and Samani, N.J. (2002) Chromosome 1 blood pressure QTL region influences renal function curve and salt sensitivity in SHR. Physiol. Genom., 8, 15–21.[Abstract/Free Full Text]

  39. Cui, Z.H., Nemoto, K., Kawakami, K., Gonda, T., Nabika, T. and Masuda, J. (2002) Fine linkage mapping of the blood pressure quantitative trait locus region on rat chromosome 1. Hypertens. Res., 25, 605–608.[CrossRef][Web of Science][Medline]

  40. Clemitson, J.R., Pratt, J.R., Frantz, S., Sacks, S. and Samani, N.J. (2002) Kidney specificity of rat chromosome 1 blood pressure quantitative trait locus region. Hypertension, 40, 292–297.[Abstract/Free Full Text]

  41. Monti, J., Plehm, R., Schulz, H., Ganten, D., Kreutz, R. and Hubner, N. (2003) Interaction between blood pressure quantitative trait loci in rats in which trait variation at chromosome 1 is conditional upon a specific allele at chromosome 10. Hum. Mol. Genet., 12, 435–439.[Abstract/Free Full Text]

  42. Yagil, C., Hubner, N., Kreutz, R., Ganten, D. and Yagil, Y. (2003) Congenic strains confirm the presence of salt-sensitivity QTLs on chromosome 1 in the Sabra rat model of hypertension. Physiol. Genom., 12, 85–95.[Abstract/Free Full Text]

  43. Garrett, M.R., Zhang, X., Dukhanina, O.I., Deng, A.Y. and Rapp, J.P. (2001) Two linked blood pressure quantitative trait loci on chromosome 10 defined by dahl rat congenic strains. Hypertension, 38, 779–785.[Abstract/Free Full Text]

  44. Alemayehu, A., Breen, L., Krenova, D. and Printz, M.P. (2002) Reciprocal rat chromosome 2 congenic strains reveal contrasting blood pressure and heart rate QTL. Physiol. Genom., 10, 199–210.[Abstract/Free Full Text]

  45. Garrett, M.R. and Rapp, J.P. (2002) Multiple blood pressure QTL on rat Chromosome 2 defined by congenic Dahl rats. Mamm. Genome, 13, 41–44.[CrossRef][Web of Science][Medline]

  46. Lee, S.J., Liu, J., Qi, N., Guarnera, R.A., Lee, S.Y. and Cicila, G.T. (2003) Use of a panel of congenic strains to evaluate differentially expressed genes as candidate genes for blood pressure quantitative trait loci. Hypertens. Res., 26, 75–87.[CrossRef][Web of Science][Medline]

  47. Carr, F.J., Negrin, C.D., Clark, J.S., Graham, D., McBride, M.W., Anderson, N.W. and Dominiczak, A.F. (2002) Chromosome 2 reciprocal congenic strains to evaluate the effect of the genetic background on blood pressure. Scott. Med. J., 47, 7–9.[Web of Science][Medline]

  48. Palijan, A., Dutil, J. and Deng, A.Y. (2003) Quantitative trait loci with opposing blood pressure effects demonstrating epistasis on Dahl rat chromosome 3. Physiol. Genom., 15, 1–8.[Abstract/Free Full Text]

  49. Garrett, M.R. and Rapp, J.P. (2002) Two closely linked interactive blood pressure QTL on rat chromosome 5 defined using congenic Dahl rats. Physiol. Genom., 8, 81–86.[Abstract/Free Full Text]

  50. Pravenec, M., Kren, V., Krenova, D., Zidek, V., Simakova, M., Musilova, A., Vorlicek, J., Lezin, E.S. and Kurtz, T.W. (2003) Genetic isolation of quantitative trait loci for blood pressure development and renal mass on chromosome 5 in the spontaneously hypertensive rat. Physiol. Res., 52, 285–289.[Web of Science][Medline]

  51. Garrett, M.R. and Rapp, J.P. (2003) Defining the blood pressure QTL on chromosome 7 in Dahl rats by a 177-kb congenic segment containing Cyp11b1. Mamm. Genome, 14, 268–273.[CrossRef][Web of Science][Medline]

  52. Khan, I.M., Singletary, E., Alemayehu, A., Stanislaus, S., Printz, M.P., Yaksh, T.L. and Taylor, P. (2002) Nicotinic receptor gene cluster on rat chromosome 8 in nociceptive and blood pressure hyperresponsiveness. Physiol. Genom., 11, 65–72.[Abstract/Free Full Text]

  53. Meng, H., Garrett, M.R., Dene, H. and Rapp, J.P. (2003) Localization of a blood pressure QTL to a 2.4-cM interval on rat chromosome 9 using congenic strains. Genomics, 81, 210–220.[CrossRef][Web of Science][Medline]

  54. Moujahidine, M., Dutil, J., Hamet, P. and Deng, A.Y. (2002) Congenic mapping of a blood pressure QTL on chromosome 16 of Dahl rats. Mamm. Genome, 13, 153–156.[CrossRef][Web of Science][Medline]

  55. Deng, A.Y., Dutil, J. and Sivo, Z. (2001) Utilization of marker-assisted congenics to map two blood pressure quantitative trait loci in Dahl rats. Mamm. Genome, 12, 612–616.[CrossRef][Web of Science][Medline]

  56. Sivo, Z., Malo, B., Dutil, J. and Deng, A.Y. (2002) Accelerated congenics for mapping two blood pressure quantitative trait loci on chromosome 10 of Dahl rats. J. Hypertens., 20, 45–53.[CrossRef][Web of Science][Medline]

  57. Palijan, A., Lambert, R., Dutil, J., Sivo, Z. and Deng, A.Y. (2003) Comprehensive congenic coverage revealing multiple blood pressure quantitative trait loci on Dahl rat chromosome 10. Hypertension, 42, 515–522.[Abstract/Free Full Text]

  58. Monti, J., Zimdahl, H., Schulz, H., Plehm, R., Ganten, D. and Hubner, N. (2003) The role of Wnk4 in polygenic hypertension: a candidate gene analysis on rat chromosome 10. Hypertension, 41, 938–942.[Abstract/Free Full Text]

  59. Hubner, N., Lee, Y.A., Lindpaintner, K., Ganten, D. and Kreutz, R. (1999) Congenic substitution mapping excludes Sa as a candidate gene locus for a blood pressure quantitative trait locus on rat chromosome 1. Hypertension, 34, 643–648.[Abstract/Free Full Text]

  60. St Lezin, E., Griffin, K.A., Picken, M., Churchill, M.C., Churchill, P.C., Kurtz, T.W., Liu, W., Wang, N., Kren, V., Zidek, V. et al. (1999) Genetic isolation of a chromosome 1 region affecting susceptibility to hypertension-induced renal damage in the spontaneously hypertensive rat. Hypertension, 34, 187–191.[Abstract/Free Full Text]

  61. Cicila, G.T., Choi, C., Dene, H., Lee, S.J. and Rapp, J.P. (1999) Two blood pressure/cardiac mass quantitative trait loci on chromosome 3 in Dahl rats. Mamm. Genome, 10, 112–116.[CrossRef][Web of Science][Medline]

  62. Podolin, P.L., Armitage, N., Lord, C.J., Levy, E.R., Peterson, L.B., Todd, J.A., Wicker, L.S. and Lyons, P.A. (1998) Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse chromosome 3. Mamm. Genome, 9, 283–286.[CrossRef][Web of Science][Medline]

  63. Serreze, D.V., Bridgett, M., Chapman, H.D., Chen, E., Richard, S.D. and Leiter, E.H. (1998) Subcongenic analysis of the Idd13 locus in NOD/Lt mice: evidence for several susceptibility genes including a possible diabetogenic role for beta 2-microglobulin. J. Immunol., 160, 1472–1478.[Abstract/Free Full Text]

  64. Lifton, R.P., Dluhy, R.G., Powers, M., Rich, G.M., Cook, S., Ulick, S. and Lalouel, J.M. (1992) A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature, 355, 262–265.[CrossRef][Medline]

  65. Aitman, T.J., Glazier, A.M., Wallace, C.A., Cooper, L.D., Norsworthy, P.J., Wahid, F.N., Al-Majali, K.M., Trembling, P.M., Mann, C.J., Shoulders, C.C. et al. (1999) Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat. Genet., 21, 76–83.[CrossRef][Web of Science][Medline]

  66. McBride, M.W., Carr, F.J., Graham, D., Anderson, N.H., Clark, J.S., Lee, W.K., Charchar, F.J., Brosnan, M.J. and Dominiczak, A.F. (2003) Microarray analysis of rat chromosome 2 congenic strains. Hypertension, 41, 847–853.[Abstract/Free Full Text]

  67. Hannon, G.J. (2002) RNA interference. Nature, 418, 244–251.[CrossRef][Medline]

  68. Shimkets, R.A., Warnock, D.G., Bositis, C.M., Nelson-Williams, C., Hansson, J.H., Schambelan, M., Gill, J.R., Jr, Ulick, S., Milora, R.V., Findling, J.W. et al. (1994) Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell, 79, 407–414.[CrossRef][Web of Science][Medline]

  69. Snyder, P.M., Steines, J.C. and Olson, D.R. (2003) Relative contribution of Nedd4 and Nedd4-2 to ENaC regulation in epithelia determined by RNA interference. J. Biol. Chem., 279, 5042–5046.

  70. Sacks, F.M., Svetkey, L.P., Vollmer, W.M., Appel, L.J., Bray, G.A., Harsha, D., Obarzanek, E., Conlin, P.R., Miller, E.R. 3rd, Simons-Morton, D.G. et al. (2001) Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N. Engl. J. Med., 344, 3–10.[Abstract/Free Full Text]

  71. Turnbull, F. (2003) Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 362, 1527–1535.[CrossRef][Web of Science][Medline]

  72. Wolf-Maier, K., Cooper, R.S., Kramer, H., Banegas, J.R., Giampaoli, S., Joffres, M.R., Poulter, N., Primatesta, P., Stegmayr, B. and Thamm, M. (2004) Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension, 43, 10–17.[Abstract/Free Full Text]

  73. Koopmans, R.P., Insel, P.A. and Michel, M.C. (2003) Pharmacogenetics of hypertension treatment: a structured review. Pharmacogenetics, 13, 705–713.[CrossRef][Web of Science][Medline]

  74. Turner, S.T., Chapman, A.B., Schwartz, G.L. and Boerwinkle, E. (2003) Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am. J. Hypertens., 16, 834–839.[CrossRef][Web of Science][Medline]

  75. Liljedahl, U., Karlsson, J., Melhus, H., Kurland, L., Lindersson, M., Kahan, T., Nystrom, F., Lind, L. and Syvanen, A.C. (2003) A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics, 13, 7–17.[CrossRef][Web of Science][Medline]

  76. Gibbs, R.A. and Belmont, J.W. and Hardenbol, P. and Willis, T.D. and Yu, F. and Yang, H. and Ch'ang, L.Y. and Huang, W. and Liu, B. and Shen, Y. et al. (2003) The International HapMap Project. Nature, 426, 789–796.[CrossRef][Medline]

  77. Perola, M., Kainulainen, K., Pajukanta, P., Terwilliger, J.D., Hiekkalinna, T., Ellonen, P., Kaprio, J., Koskenvuo, M., Kontula, K. and Peltonen, L. (2000) Genome-wide scan of predisposing loci for increased diastolic blood pressure in Finnish siblings. J. Hypertens., 18, 1579–1585.[CrossRef][Web of Science][Medline]

  78. Harrap, S.B., Wong, Z.Y., Stebbing, M., Lamantia, A. and Bahlo, M. (2002) Blood pressure QTLs identified by genome-wide linkage analysis and dependence on associated phenotypes. Physiol. Genom., 8, 99–105.[Abstract/Free Full Text]

  79. Hsueh, W.C., Mitchell, B.D., Schneider, J.L., Wagner, M.J., Bell, C.J., Nanthakumar, E. and Shuldiner, A.R. (2000) QTL influencing blood pressure maps to the region of PPH1 on chromosome 2q31–34 in Old Order Amish. Circulation, 101, 2810–2816.[Abstract/Free Full Text]

  80. Krushkal, J., Ferrell, R., Mockrin, S.C., Turner, S.T., Sing, C.F. and Boerwinkle, E. (1999) Genome-wide linkage analyses of systolic blood pressure using highly discordant siblings. Circulation, 99, 1407–1410.[Abstract/Free Full Text]

  81. Rao, D.C., Province, M.A., Leppert, M.F., Oberman, A.l., Heiss, G., Ellison, R.C., Arnett, D.K., Eckfeldt, J.H., Schwander, K., Mockrin, S.C. et al. (2003) A genome-wide affected sibpair linkage analysis of hypertension: the HyperGEN network. Am. J. Hypertens., 16, 148–150.

  82. Moses, E.K., Lade, J.A., Guo, G., Wilton, A.N., Grehan, M., Freed, K., Borg, A., Terwilliger, J.D., North, R., Cooper, D.W. et al. (2000) A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. Am. J. Hum. Genet., 67, 1581–1585.[CrossRef][Web of Science][Medline]

  83. Arngrimsson, R., Sigurard ttir, S., Frigge, M.L., Bjarnadttir, R.I., Jonsson, T., Stefansson, H., Baldursdottir, A., Einarsdottir, A.S., Palsson, B., Snorradottir, S. et al. (1999) A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum. Mol. Genet., 8, 1799–1805.[Abstract/Free Full Text]

  84. Rice, T., Rankinen, T., Province, M.A., Chagnon, Y.C., Perusse, L., Borecki, I.B., Bouchard, C. and Rao, D.C. (2000) Genome-wide linkage analysis of systolic and diastolic blood pressure: the Quebec Family Study. Circulation, 102, 1956–1963.[Abstract/Free Full Text]

  85. Xu, X., Rogus, J.J., Terwedow, H.A., Yang, J., Wang, Z., Chen, C., Niu, T., Wang, B., Xu, H., Weiss, S. et al. (1999) An extreme-sib-pair genome scan for genes regulating blood pressure. Am. J. Hum. Genet., 64, 1694–1701.[CrossRef][Web of Science][Medline]

  86. Allayee, H., de Bruin, T.W., Michelle Dominguez, K., Cheng, L.S., Ipp, E., Cantor, R.M., Krass, K.L., Keulen, E.T., Aouizerat, B.E., Lusis, A.J. et al. (2001) Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. Hypertension, 38, 773–778.[Abstract/Free Full Text]

  87. Pankow, J.S., Rose, K.M., Oberman, A., Hunt, S.C., Atwood, L.D., Djousse, L., Province, M.A. and Rao, D.C. (2000) Possible locus on chromosome 18q influencing postural systolic blood pressure changes. Hypertension, 36, 471–476.[Abstract/Free Full Text]

  88. Hunt, S.C., Ellison, R.C., Atwood, L.D., Pankow, J.S., Province, M.A. and Leppert, M.F. (2002) Genome scans for blood pressure and hypertension: the National Heart, Lung, and Blood Institute Family Heart Study. Hypertension, 40, 1–6.[Abstract/Free Full Text]

  89. Sharma, P., Fatibene, J., Ferraro, F., Jia, H., Monteith, S., Brown, C., Clayton, D., O'Shaughnessy, K. and Brown, M.J. (2000) A genome-wide search for susceptibility loci to human essential hypertension. Hypertension, 35, 1291–1296.[Abstract/Free Full Text]

  90. Rice, T., Rankinen, T., Chagnon, Y.C., Province, M.A., Perusse, L., Leon, A.S., Skinner, J.S., Wilmore, J.H., Bouchard, C. and Rao, D.C. (2002) Genomewide linkage scan of resting blood pressure: HERITAGE Family Study. Health, Risk Factors, Exercise Training, and Genetics. Hypertension, 39, 1037–1043.[Abstract/Free Full Text]

  91. Ranade, K., Hsuing, A.C., Wu, K.D., Chang, M.S., Chen, Y.T., Hebert, J., Chen, Y.I., Olshen, R., Curb, D., Dzau, V. et al. (2000) Lack of evidence for an association between alpha-adducin and blood pressure regulation in Asian populations. Am. J. Hypertens., 13, 704–709.[CrossRef][Web of Science][Medline]

  92. Kristjansson, K., Manolescu, A., Kristinsson, A., Hardarson, T., Knudsen, H., Ingason, S., Thorleifsson, G., Frigge, M.L., Kong, A., Gulcher, J.R. et al. (2002) Linkage of essential hypertension to chromosome 18q. Hypertension, 39, 1044–1049.[Abstract/Free Full Text]

  93. Cooper, R.S., Luke, A., Zhu, X., Kan, D., Adeyemo, A., Rotimi, C., Bouzekri, N., Ward, R. and Rorimi, C. (2002) Genome scan among Nigerians linking blood pressure to chromosomes 2, 3, and 19. Hypertension, 40, 629–633.[Abstract/Free Full Text]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Phil Trans R Soc BHome page
Y. Shen, Q. Xu, Z. Han, H. Liu, and G.-B. Zhou
Analysis of phenotype-genotype connection: the story of dissecting disease pathogenesis in genomic era in China, and beyond
Phil Trans R Soc B, June 29, 2007; 362(1482): 1043 - 1061.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
K. Yatsu, N. Mizuki, N. Hirawa, A. Oka, N. Itoh, T. Yamane, M. Ogawa, T. Shiwa, Y. Tabara, S. Ohno, et al.
High-Resolution Mapping for Essential Hypertension Using Microsatellite Markers
Hypertension, March 1, 2007; 49(3): 446 - 452.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
P. B. Munroe, C. Wallace, M.-Z. Xue, A. C. B. Marcano, R. J. Dobson, A. K. Onipinla, B. Burke, J. Gungadoo, S. J. Newhouse, J. Pembroke, et al.
Increased Support for Linkage of a Novel Locus on Chromosome 5q13 for Essential Hypertension in the British Genetics of Hypertension Study
Hypertension, July 1, 2006; 48(1): 105 - 111.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
M. Ciullo, C. Bellenguez, V. Colonna, T. Nutile, A. Calabria, R. Pacente, G. Iovino, B. Trimarco, C. Bourgain, and M. G. Persico
New susceptibility locus for hypertension on chromosome 8q by efficient pedigree-breaking in an Italian isolate
Hum. Mol. Genet., May 15, 2006; 15(10): 1735 - 1743.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. J. Morris
Dissecting Hypertension by Obesity Identifies a Locus at 1p36
Hypertension, December 1, 2005; 46(6): 1256 - 1258.
[Full Text] [PDF]


Home page
HypertensionHome page
W. Chen, S. Li, S. R Srinivasan, E. Boerwinkle, and G. S. Berenson
Autosomal Genome Scan for Loci Linked to Blood Pressure Levels and Trends Since Childhood: The Bogalusa Heart Study
Hypertension, May 1, 2005; 45(5): 954 - 959.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
P. Meneton, X. Jeunemaitre, H. E. de Wardener, and G. A. Macgregor
Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases
Physiol Rev, April 1, 2005; 85(2): 679 - 715.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
F. C. Luft
Geneticism of Essential Hypertension
Hypertension, June 1, 2004; 43(6): 1155 - 1159.
[Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
13/suppl_1/R169    most recent
ddh078v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mein, C. A.
Right arrow Articles by Munroe, P. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mein, C. A.
Right arrow Articles by Munroe, P. B.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?